There have been a series of recalls involving several well-known high blood pressure medications. Some of these medications, offered by different manufacturers include Losartan, Valsartan, and Irbesartan. A massive recall came from Aurobindo Pharma USA, who voluntarily recalled over 80 lots of their popular high blood pressure medications, including the following:
- Valsartan HCTZ Tablets
- Amlodipine Valsartan Tablets USP
- Valsartan Tablets USP
Nearly 80 million high blood pressure prescriptions have been written since 2016. Beyond that, many people who have come to rely on these medications are now left scrambling to find alternatives.
Patients are now filing lawsuits against the manufacturers of Valsartan alleging that many batches of the drug from 2012 to 2018 were contaminated with N-nitrosodimethylamine (NDMA), a probable carcinogen.
Valsartan lawsuits are based on the following criteria:
- The plaintiff used Valsartan for at least one year in 2014 or later
- After at least one year of taking Valsartan, the plaintiff was diagnosed with:
- Liver Cancer
- Kidney Cancer
- Stomach Cancer
- Intestinal Cancer
- Colon and Rectal Cancer
Lawsuits are starting to be filed in cases relating to the heart drug Valsartan. The drug recall was announced about a year ago and new carcinogens are still being discovered in this class of medications. Around the first 50 of these lawsuits have been consolidated into multi-district litigation in federal court in New Jersey. The full impact that drugs like Valsartan had on patients has yet to be determined. Although only a handful of lawsuits have been filed so far, it is anticipated that several thousand lawsuits will eventually be filed as patients begin to realize the extent of the harm they have suffered from taking these medications. There are several different drugs in the class and each has been found to have been tainted. This will further expand the pool of lawsuits. The relevant lawsuits recently achieved multi-district status in February 2019 so these cases are still in the development phase. There is not yet any discovery scheduled and any bellwether cases are still far in the future. It is likely that the scope of these lawsuits may change as more is revealed about the character and extent of the contaminants impacting the medications.